Point-of-care molecular diagnostics instrumentation

Biocartis is a commercial stage company which develops novel molecular diagnostics. The proprietary Idylla™ platform is a fully automated, real-time system which provides accurate, highly-reliable RNA and protein expression information from any biological sample, thus improving diagnosis and facilitating personalised therapy at the point of care.

CEO  Rudi Pauwels

Advent Contact  Raj Parekh

Advent invested in the Series A in 2009. Biocartis listed on Euronext Brussels in 2015 (EBR:BCART).
Publicly Listed